Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given a consensus recommendation of “Moderate Buy” by the twenty-five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, sixteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $973.13.

Several research analysts recently commented on the company. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Finally, Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. Finally, Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.6 %

Shares of REGN opened at $674.27 on Friday. Regeneron Pharmaceuticals has a 52 week low of $642.00 and a 52 week high of $1,211.20. The firm has a market capitalization of $74.10 billion, a P/E ratio of 17.61, a P/E/G ratio of 2.38 and a beta of 0.08. The company has a 50-day simple moving average of $710.88 and a 200-day simple moving average of $901.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the firm posted $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.